November 2023
-
11.13.2023 Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
October 2023
-
10.25.2023 Vaccines Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices -
10.13.2023 Medicines Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma -
10.05.2023 Medicines FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™ -
10.02.2023 Updates & Statements Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter
September 2023
-
09.25.2023 Updates & Statements Responsibility Pfizer’s Rocky Mount Facility Restarts Production Amid First Phase of Post-Tornado Recovery Efforts -
09.07.2023 Vaccines Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
July 2023
-
07.21.2023 Medicines Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment -
07.21.2023 Vaccines Pfizer Receives Positive CHMP Opinion for RSV Vaccine Candidate to Help Protect Infants through Maternal Immunization and Older Adults
June 2023
-
06.30.2023 Vaccines Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics -
06.23.2023 Vaccines Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine -
06.23.2023 Vaccines Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine